Research/Valuation, page-362

Thanks for sharing.

Personally, I think we’ve got a higher baseline than that. I’d be shocked to see less than $10/share based on what we’ve seen in trial data and other industry M&As to date.

I also don’t believe that kind of commentary is the reason for the move we experienced towards the end of last week. That move was outstanding and a run like that doesn’t happen without a significant catalyst. And us retail plebs are always the last to know about these things. So what made some big players throw (relatively speaking) caution to the wind and allow the price to run like that last week? Is there some other big trial news coming? I’m excited to see what could be coming because that run was not at all common!